Hologic, Inc. (NASDAQ:HOLX) Stake Trimmed by QRG Capital Management Inc.

QRG Capital Management Inc. lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 86,967 shares of the medical equipment provider’s stock after selling 5,509 shares during the quarter. QRG Capital Management Inc.’s holdings in Hologic were worth $6,269,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. General Partner Inc. acquired a new stake in shares of Hologic in the fourth quarter worth $26,000. Groupama Asset Managment raised its position in Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares during the period. Venturi Wealth Management LLC lifted its stake in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 261 shares in the last quarter. First Horizon Advisors Inc. boosted its position in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the period. Finally, Covestor Ltd grew its stake in Hologic by 23.8% during the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 133 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on HOLX shares. Mizuho cut their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Leerink Partnrs downgraded Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Royal Bank of Canada cut their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday, February 6th. Finally, StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Ten research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $85.77.

Hologic Trading Up 0.3 %

Shares of NASDAQ:HOLX opened at $63.38 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52-week low of $62.69 and a 52-week high of $84.67. The company has a 50-day simple moving average of $69.16 and a 200 day simple moving average of $75.97. The company has a market capitalization of $14.22 billion, a P/E ratio of 19.99, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.88% of the stock is owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.